Why Celcuity Inc.’s (CELC) Stock Is Up 6.92%
As of Friday, August 14, Celcuity Inc.’s CELC share price has surged by 6.92%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Commentary & Analysis
Why Celcuity Inc.’s (CELC) Stock Is Down 5.21%
As of Thursday, July 16, Celcuity Inc.’s CELC share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Celcuity Inc.’s (CELC) Stock Is Down 14.45%
As of Wednesday, July 15, Celcuity Inc.’s CELC share price has dipped by 14.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Celcuity Inc.’s (CELC) Stock Is Down 20.08%
As of Wednesday, July 15, Celcuity Inc.’s CELC share price has dipped by 20.08%, which has investors questioning if this is right time to buy.Tudor Pop
Why Celcuity Inc.’s (CELC) Stock Is Down 5.40%
As of Friday, July 10, Celcuity Inc.’s CELC share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CELC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,682.8 | $282.4 | 66% |
|
| Shares Out (Mil) | 54.8 | 54.0 | 50% |
|
| Institutional Ownership | 89.8% | 93.1% | 57% |
|
| Float (Mil) | 29.7 | 42.2 | 36% |
|
| Beta | 0.20 | 0.94 | 13% |
|
| Avg Daily Volume (000s) | 700 | 482 | 66% |
|
| Price Change (52-week) |
75.7% | 59.9% | 88% |
|
| Growth | CELC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (79.5%) | (10.1%) | 3% |
|
| EPS (5yr) | (32.6%) | 15.9% | 7 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 45.1% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.510) | ($4.390) | ($0.080) | |
| Month Ago EPS | ($1.180) | ($3.770) | $0.960 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($1.085) | ($3.530) | $0.740 | |
| Year/Year Chg | 4.9% | 16.0% | (222.0%) | |
| Financials | CELC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($227) | ($43) | 6% |
|
| EPS (TTM) | ($4.322) | ($1.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($192) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $136 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $754 | $4 | 63% |
|
| Enterprise Value (Q1) (Mil) | $4,502 | $190 | 61% |
|
| Valuation | CELC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CELC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (44.8%) | (47.7%) | 13% |
|
| ROE | na | (55.0%) | na |
|
| Liabilities to Assets | 101.5% | 29.8% | 94% |
|
| F-Score | 3 | 3 | 18% |
|
Celcuity Inc. did not pass any screens on 9/4/2026.
